Finance

Lists
STIM:NASDAQ
Neuronetics Inc
$2.94
-0.68%
(-0.020) 1D
$2.97
+0.89% (+0.026)
After hours
Closed: Aug 28, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for STIM...
Open
$2.96
High
$3.02
Low
$2.88
Mkt. cap
224.02M
Avg. vol.
2.68M
Volume
865.14K
52-wk high
$3.71
52-wk low
$0.80
EPS
-$0.44
Beta
1.03
Shares outstanding
76.20M
No. of employees
658
Open
$2.96
High
$3.02
Low
$2.88
Mkt. cap
224.02M
Avg. vol.
2.68M
Volume
865.14K
52-wk high
$3.71
52-wk low
$0.80
EPS
-$0.44
Beta
1.03
Shares outstanding
76.20M
No. of employees
658
News stories
From web sources and news partners
Profile
Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology. Neuronetics became the "first and only Food and Drug Administration approval for the clinical treatment of a specific form of medication-refractory depression using a TMS Therapy device." They manufacture a transcranial magnetic stimulation device, NeuroStar. The NeuroStar TMS therapy is delivered via a precisely positioned magnetic coil against the patient's head. Wikipedia
About Neuronetics Inc
CEO-
Employees658
Founded2003
HeadquartersMalvern, Pennsylvania, United States
SectorMedical device
Websiteneurostar.com
Analyst ratings
Based on 1 analyst giving stock ratings to STIM in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for STIM in the last 3 months
Highest
Current $2.94
$5.00 (+70.07%)
Average
$5.00 (+70.07%)
Lowest
$5.00 (+70.07%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sam Eiber
BTIG
Buy
Initiated
$5.00
+70.1%
07/20/2026
William Plovanic
Canaccord Genuity
Buy
Maintained
$3.00
+2%
04/06/2026
Adam Maeder
Piper Sandler
Buy
Maintained
$3.00
+2%
04/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
37.30M
41.78M
34.45M
41.57M
Cost of goods sold
20.19M
19.67M
18.30M
20.34M
Cost of revenue
20.19M
19.67M
18.30M
20.34M
Research and development expenses
1.50M
1.67M
1.36M
1.34M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
22.92M
25.08M
23.78M
21.39M
Operating expense
24.43M
26.75M
25.15M
22.72M
Total operating expenses
44.62M
46.42M
43.45M
43.07M
Operating income
-7.32M
-4.64M
-9.00M
-1.50M
Other non operating income
-
-
-
-
EBT including unusual items
-9.40M
-7.21M
-10.78M
-3.46M
EBT excluding unusual items
-9.40M
-6.81M
-10.24M
-3.46M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-9.04M
-7.16M
-10.79M
-3.44M
Net profit margin
-24.25%
-17.13%
-31.32%
-8.27%
Earnings per share
-0.13
-0.10
-0.15
-0.04
Interest and investment income
126.00K
155.00K
1.02M
162.00K
Interest expense
-2.21M
-2.32M
-2.27M
-2.12M
Net interest expenses
-2.08M
-2.16M
-1.25M
-1.96M
Depreciation and amortization charges
-
-
-
-
EBITDA
-6.44M
-3.94M
-8.27M
-782.00K
Gain or loss from assets sale
2.00K
27.00K
270.00K
99.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps